Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 5c ; Offers Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.36), $0.05 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $33.7 million versus the consensus estimate of $35.57 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2024 revenue of $140-160 million, versus the consensus of $157.9 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance